aschnell001

aschnell001

Sometime this week we may see the share price of AMEX:SENS drop to $0.78. Anything lower could indicate a drop out of the trend, but if it holds, a large profit could be made moving into August. Using a combination of the following 3 scripts: 1. Advanced Price Direction Algorithm 2. DeQuex Algo 3. Moving Average Convergence Divergence If all 3 give off a...

aschnell001

Just like $VTGN, $LIACF is an investment, not a trade.

aschnell001

The RSI, Stochastic Indicator, and Support levels are all giving good signs of a potential increase in share price. Right now I would rate it a "weak buy" until there is more of a confirmation of an upward motion.

aschnell001

Zillow will continue to drop as long as there are price reductions and they lose money on their shady deals. They've been lying to everyone about how the housing market is secure and going to continue to boom. Apart from their imminent downfall for the remainder of this year, the market itself is going to crash: If we look at the current state of the market, the...

aschnell001

Volume fell today along with the stock, which is a good sign as volume should follow the stock. Major support is around the corner, so there is a good chance that the stock will bounce back. The overall, bullish trend has been strong.

aschnell001

STOCK PRICE TARGETS High: $15.00 Median: $12.00 Low: $9.00 Average: $11.98 ANALYST RATINGS 3M AGO 1M AGO CURRENT Buy 18 17 16 Overweight 0 0 1 Hold 1 0 0 Underweight 0 0 0 Sell 1 1 1 CONSENSUS BUY BUY BUY 1) For long-term investors, this price is a bargain. 2) For short-term traders, this stock probably has at least another dollar to...

aschnell001

The S&P 500 is going to crash. As you can see in the chart, the time cycles alongside the RSI couldn't make it any more clear. Nearly every time the index broke outside the green, it fell to some degree. With inflation, the School Loan Moratorium, the Eviction Moratorium, and several other forms of excessive bureaucracy that are stifling real economic recovery...

aschnell001

Follow the trend! PALISADE Phase 3 Clinical Program for PH94B: The PALISADE Phase 3 clinical program has been initiated to evaluate the efficacy and safety of PH94B for the acute treatment of anxiety in adults with Social Anxiety Disorder (SAD). PH94B is an odorless, rapid-onset, investigational pherine nasal spray with a unique mechanism of action, working...

aschnell001

Despite having fallen out of its upward trend, I am still bullish about this stock for several different reasons: 1) The RSI is indicating that LBRT is nearly oversold 2) LBRT is capable of finding support at around $9.33 3) LBRT is currently undervalued based on yesterday's movements between high, low, and closing price. 4) Although downgraded, on August 03,...

aschnell001

The stock is currently undervalued based on yesterday's movements and the RSI. It has great support and a high probability of increasing in price. Volume fell together with the price and this reduces the overall risk as volume should follow the price movements.

aschnell001

LBRT has been a short-term sell candidate since around 2021-06-28, having a loss of -15.90%, but I think that based on the current trend it is in, the stock should continue on upwards in the upcoming days. A fair opening price for tomorrow (July 16, 2021) would be $12.25 according to StockInvest.us, so that would mean LBRT is currently undervalued at $12.06.

aschnell001

Based on 4 Wall Street analysts offering 12-month price targets for VistaGen Therapeutics in the last 3 months, the average price target is $7.00 with a high forecast of $9.00 and a low forecast of $5.00. The average price target represents a 123.64% change from the last price of $3.13.

aschnell001

IBIO is one of those stocks that does not look that great on the historical charts, but it does look great on paper. Based on what can be found online, they appear to have tons of value and the potential to boom in the upcoming years due to their concept of FastPharming. I look forward to seeing what they have in store for the future with their pending product...

aschnell001 Updated 

There has been a good upward trend over the past year. The RSI is saying it's overbought, and that can be backed up by the trendline, so DO NOT buy right now. Your best bet would be to jump in at around $12.50, assuming the trend continues as expected. Inflation should help this stock perform well.